13 results about "Corneal endothelial cell" patented technology

Congenital hereditary endothelial dystrophy (CHED) is an autosomal recessive condition affecting the corneal endothelial cells, which function to maintain corneal clarity. Currently there is no highly efficacious treatment available for CHED caused by SLC4A11 gene mutations. The invention disclosed herein includes mammalian vectors for use in the treatment of Congenital hereditary endothelial dystrophy and methods for using such vectors.

The present invention relates to the use of corneal cell-derived mitochondria for the prevention or treatment of corneal damage or corneal endothelial cell diseases. It has been confirmed that mitochondria isolated from corneal endothelial cells differentiated from induced pluripotent stem cells (iPSCs) of the present invention alleviate the inflammatory response of corneal endothelial cells in an inflammatory environment, restore the integrity and function of corneal endothelial cells, and, when delivered into heterologous primary corneal endothelial cells, suppress inflammatory responses, particularly inflammation caused by physical damage, and promote the regeneration of corneal endothelial cells. Therefore, mitochondria possessing such effects can overcome the tumorigenic limitations of conventional stem cell therapies, and due to their ease of production and minimal regulatory requirements, they offer excellent cost-effectiveness and broad applicability.

The application provides an application of alpha-ketoglutaric acid in improving corneal endothelial injury and dysfunction, and belongs to the technical field of biological medicine. The application finds that, as a key metabolic intermediate in the tricarboxylic acid cycle, alpha-ketoglutaric acid can significantly reduce corneal endothelial cell injury and dysfunction induced by various causes such as high glucose, genetic defects, high intraocular pressure and surgical trauma by improving mitochondrial energy metabolism, reducing oxidative stress, stabilizing mitochondrial structure and membrane potential. Experiments prove that alpha-ketoglutaric acid can be used in the form of local administration such as eye drops, anterior chamber perfusion, systemic oral administration or combined administration, effectively reduces corneal edema, reduces central corneal thickness, shortens the recovery time of corneal transparency, and has a clear protection and repair effect on diabetic-related corneal endothelial lesions, Fuchs corneal endothelial dystrophy, glaucoma high intraocular pressure injury and intraocular surgery-related endothelial injury.

Provided are compositions comprising aggregates of corneal endothelial cells (CECs) and methods administering said aggregates to patients for the treatment of corneal endothelial disease.

Provided are compositions comprising aggregates of corneal endothelial cells (CECs) and methods administering said aggregates to patients for the treatment of corneal endothelial disease.

A method for preparing an exosome includes: cultivating corneal stromal keratocytes (CSKs) in a culture medium containing vitamin C, so as to obtain a cell culture of the CSKs containing the exosome; and subjecting the cell culture to an isolation treatment, so as to obtain the exosome. An exosome prepared by the aforesaid method, and methods for promoting proliferation of corneal endothelial cells and improving wound healing in a corneal endothelium using the exosome are also provided.

The present disclosure provides: a method for washing corneal endothelial cells; and a method for producing a corneal endothelial cell preparation. In one aspect, the present disclosure provides a method for producing a corneal endothelial cell preparation, the method comprising a step for washing a corneal endothelial cell or a corneal endothelium-like cell with a solution containing about 0.01% by weight to about 10% by weight of a protein and a step for mixing the corneal endothelial cell or the corneal endothelium-like cell with a composition for preparation production use to produce a corneal endothelial preparation, in which the protein is selected from the group consisting of human serum albumin, casein, lactoferrin, ovalbumin, and combinations thereof.

Provided are methods of treating or preventing corneal endothelial disease. The present disclosure relates to corneal endothelial cell compositions comprising cultured human corneal endothelial cells and a Rho-associated, coiled-coil containing protein kinase inhibitor, and uses of the compositions for the treatment of corneal endothelial diseases, including bullous keratopathy, corneal edema, corneal leukoma, corneal endothelial inflammation, and corneal dystrophy.

The present invention relates to a method of inducing differentiation of stem cells into corneal endothelial cells and use thereof. The method according to an aspect may increase, by using a composition for differentiation, the efficiency of differentiating stem cells into corneal endothelial cells. The differentiated corneal endothelial cells exhibit specific characteristics of corneal endothelial cells, and thus can be widely used as an alternative cell source for transplantation of corneal endothelial cells. Additionally, since FBS is not contained, stability in clinical trials may be improved.

Provided is a pharmaceutical composition for preventing or treating diseases or conditions associated with corneal endothelial disorders.　It was discovered that, in diseases or conditions associated with corneal endothelial disorders, a compound having an estrogen activity inhibits the decrease in the density of corneal endothelial cells and inhibits the production of an extracellular matrix.